Eli Lilly LLY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $72.25B+47.4% | $65.18B+44.7% | $59.42B+45.4% | $53.26B+36.8% | $49B+36.4% | ||
| $12.4B+38.3% | $11.05B+31.3% | $10.08B+29.3% | $9.25B+23.4% | $8.97B+25.8% | ||
| $59.84B+49.5% | $54.13B+47.8% | $49.34B+49.2% | $44.01B+40.0% | $40.03B+39.0% | ||
| 82.8%+1.1pp | 83%+1.7pp | 83%+2.1pp | 82.6%+1.9pp | 81.7%+1.5pp | ||
| $14.11B+26.0% | $13.34B+21.3% | $12.56B+19.3% | $11.83B+15.9% | $11.2B+13.7% | ||
| $11.56B+26.9% | $11.09B+29.1% | $10.39B+28.3% | $9.75B+25.0% | $9.11B+19.8% | ||
| -$397M+18.2% | -$571M-161% | -$573.2M-4,578% | -$378.1M-422% | -$485.1M-649% | ||
| $31.13B+129% | $25.73B+103% | $22.5B+122% | $16.86B+87.6% | $13.6B+79.9% | ||
| $5.85B+135% | $5.09B+144% | $4.09B+130% | $3.06B+85.8% | $2.49B+75.3% | ||
| $25.28B+128% | $20.64B+94.9% | $18.41B+120% | $13.8B+88.0% | $11.11B+80.9% | ||
| 35%+12.3pp | 31.7%+8.2pp | 31%+10.5pp | 25.9%+7.0pp | 22.7%+5.6pp | ||
| $28.15+129% | $22.95+96.0% | $20.44+121% | $15.30+88.4% | $12.29+81.0% | ||
| $33.17B+115% | $27.73B+91.9% | $24.4B+106% | $18.75B+76.9% | $15.43B+69.1% | ||
| 45.9%+14.4pp | 42.5%+10.5pp | 41.1%+12.1pp | 35.2%+8.0pp | 31.5%+6.1pp | ||
| $31.13B+129% | $25.73B+103% | $22.5B+122% | $16.86B+87.6% | $13.6B+79.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Eli Lilly's revenue?
- Eli Lilly (LLY) generated $72.2B in revenue over the trailing twelve months, up 47.4% year over year.
- Is Eli Lilly profitable?
- Eli Lilly reported $25.3B in net income over the trailing twelve months, a 35.0% net margin.
- What is Eli Lilly's earnings per share?
- Eli Lilly's diluted EPS over the trailing twelve months is $28.15.
- Where does Eli Lilly's income statement data come from?
- Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
